

NDA 22408/S-10

**NOTIFICATION OF
NON-COMPLIANCE WITH PREA**

Cipher Pharmaceuticals Inc.
c/o VCLS Inc.
Attention: Allison Mital
Authorized U.S. Agent
50 Division St., Suite 206
Somerville, NJ 08876

Dear Allison Mital:

Please refer to your supplemental new drug application (sNDA) submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for Natroba (spinosad) topical suspension, which was approved on April 28, 2021.

The Agency has determined that you have failed to meet the postmarketing requirement (PMR) of the Pediatric Research Equity Act (PREA) for this application because you have not yet submitted your pediatric assessment for the following:

PMR 4062-1, which was deferred until March 31, 2026.

Therefore, we are hereby notifying you that due to your failure to submit either a pediatric assessment or a request for a deferral extension, you are not in compliance with federal law.

Under the provisions of section 505B(d)(1) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. 355c(d)(1)], you must respond in writing within 45 calendar days of the date of this letter. Your response should include the reason(s) for the delayed pediatric assessment and a date by which you expect to submit the assessment. You may also include a request for a deferral extension, if applicable, which should be identified as a **"DEFERRAL EXTENSION REQUESTED"** in your response.

In accordance with the FD&C Act, FDA will post this letter and your response to the website at <https://www.fda.gov/drugs/development-resources/non-compliance-letters-under-505bd1-federal-food-drug-and-cosmetic-act> with redactions for any trade secrets and confidential commercial information 60 calendar days from the date of this letter.

Please identify your response to this letter as a **"RESPONSE TO PREA NON-COMPLIANCE LETTER."** To facilitate our review, submit this information to your sNDA

with a cross-reference letter to the investigational new drug application (IND) to which your protocol has been submitted.

If you have any questions, contact Emilija Renke, Regulatory Project Manager, at Emilija.Renke@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Tatiana Oussova, MD, MPH
Deputy Director for Safety
Division of Dermatology and Dentistry
Office of Immunology and Inflammation
Office of New Drugs
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.

/s/

TATIANA OUSSOVA
04/23/2026 11:01:37 AM